Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228176 · ClinicalTrials.gov registry record · Phase 3
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 661
- Enrollment target
NCT00228176 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 661 participants.
The verdict
NCT00228176, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 661 participants
- Enrollment target
Study Summary
Objectives: * Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) * Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in the study population of atherosclerosis patients.
Interventions
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228176
The ClinicalTrials.gov registry entry for NCT00228176 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimonabant is the first listed.
NCT00228176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00228176 about?
NCT00228176 is a clinical study titled "Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant". Objectives: * Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) * Secondary: To evaluate the safety and tolerability of the above rimonabant regime...
What is the current status of trial NCT00228176?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 661 participants. The study started on 2005-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00228176?
The interventions under investigation include: Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00228176?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.